NMIBC
Clinical trials for NMIBC explained in plain language.
Never miss a new study
Get alerted when new NMIBC trials appear
Sign up with your email to follow new studies for NMIBC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer drug combo shows promise in early trial
Disease control Not yet recruitingThis study tests a new drug called SPGL008, given alone or with a standard therapy (BCG), for people with a type of bladder cancer that hasn't spread into the muscle wall. The main goals are to find the safest dose and see if the drug helps control the cancer. About 120 adults wh…
Matched conditions: NMIBC
Phase: PHASE1, PHASE2 • Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. • Aim: Disease control
Last updated May 17, 2026 06:42 UTC
-
Promising drug combo aims to keep bladder cancer from returning
Disease control Not yet recruitingThis study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from coming back. About 182 adults whose cancer has been surgically removed will receive either the combination or BCG alone. The main goal is to…
Matched conditions: NMIBC
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 17, 2026 06:37 UTC
-
New combo therapy aims to fight tough bladder cancer without removing the bladder
Disease control Not yet recruitingThis phase 3 study tests a new drug (SHR-1501) given directly into the bladder along with BCG, compared to standard chemotherapy, in people with high-risk bladder cancer that no longer responds to BCG alone. The goal is to see if the combination helps keep the cancer from coming …
Matched conditions: NMIBC
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC